GLP1R and type 2 diabetes mellitus: Although not currently FDA-approved, semaglutide, a once-weekly GLP-1 agonist, was non-inferior to placebo after 26 months follow-up among 3297 patients with T2DM in the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) with regards to the primary composite endpoint of cardiovascular death, non-fatal MI and non-fatal stroke (HR 0.74, 95% CI 0.58–0.95, p < 0.001 for non- inferiority) [81].